Trauma Delirium Management Guideline

- Monitoring and Treatment
  - The confusion assessment method for the ICU (CAM-ICU) should be monitored each shift and reported to the team during rounds
    - CAM-ICU should ONLY be reported as unable to assess is RASS <-3
    - If CAM positive, consider differential diagnosis (hypoxia, sepsis, CHF, over-sedation, deliriogenic medications)
  - **Hypoactive delirium – CAM positive and RASS 0 to -3**
    - Non-pharmacological management
  - **Hyperactive or mixed hyper/hypoactive delirium – CAM positive and RASS -3 to +4**
    - See algorithm on next page
  - Goal RASS should be specified on ALL patients

- Non-pharmacologic management
  - **Orient patient** (provide visual/hearing aids, re-orient, encourage communication, encourage proper sleep hygiene, and provide cognitively stimulating activities during the day)
  - **Environment** (Mobilize patients early and often, provide familiar objects in patient’s room, minimize noise at night, and remove unnecessary lines/drains)
  - **Adjunctive** (perform SATs daily, provide adequate pain management, correct dehydration and electrolyte disturbances)

- Deliriogenic Medications
  - Benzodiazepines
  - Anticholinergics (diphenhydramine, glycopyrrolate, metoclopramide, H2 blockers, TCAs, cyclobenzaprine)
  - Steroids
  - Pain medications (if pain is not cause of agitation/delirium)
    - Decrease opioid dose
    - Utilize multimodal pain regimen
Hyperactive Delirium
(includes mixed delirium with hyperactive component, ex: attempting to wean sedation)

Delirious (CAM-ICU positive)

- Consider differential diagnosis (sepsis, alcohol withdrawal, etc)
- Remove deliriogenic medications
- Always attempt non-pharmacologic measures initially

CAM +, RASS +1 to +2

- Ensure adequate sleep and pain control
- Quetiapine 25-50mg q8-12hrs or olanzapine 2.5mg q 8-12hrs
- Haloperidol 1-10mg IV q4h prn breakthrough agitation
  - If TBI, see algorithm on right

No response at 24hrs or multiple IV doses of haloperidol

- Reassess analgesia
  - ↑quetiapine to 50-100mg q6-8hrs or olanzapine to 5-10mg q6-8hrs
  - Continue haloperidol breakthrough

CAM +, RASS +3 to +4

- Ensure adequate pain control
  - Haloperidol 5-20 mg IV/IM q15min prn extreme agitation
  - Start sedation if none currently infusing
  - Bolus (if receiving propofol) and/or increase rate of current sedative

Intubated/Trached

RASS remains ≥ +3 with multiple doses of IV haloperidol

- Ensure adequate pain control
  - Haloperidol 5-20 mg IV/IM q15min prn extreme agitation
  - Consider dexmedetomidine

Extubated

- Ensure adequate pain control
  - Haloperidol 5-20 mg IV/IM q15min prn extreme agitation
  - Consider dexmedetomidine

Traumatic Brain Injury

- Start Depakote/valproic acid 250-500 mg q8-6h (titrate up to max 60mg/kg/day, if needed)
- Consider early use of propranolol 10-20mg q8-6h (max 360 mg/day) for agitation related to neurologic storming.
- Follow algorithm (see left) for escalation of antipsychotics.

Depakote monitoring:
- Obtain baseline and weekly LFTs; discontinue VPA if:
  - AST or ALT >5x ULN OR Alk Phos >2x ULN on 2 separate occasions
  - T bili >2.5 mg/dL with elevated AST, ALT, or Alk Phos
  - INR >1.5 with elevated AST, ALT, or Alk Phos
- Use with caution in hepatic disease
- Obtain valproate level ONLY if concerned for toxicity

IMPORANT CONSIDERATIONS:

- Geriatric population (> 65 yo):
  - Reduce initial antipsychotic and Depakote/valproic acid doses by 50%
  - Avoid haloperidol doses >5mg or quetiapine doses >100mg
  - Consider trialing trazodone 25-50 mg qhs before antipsychotics if agitation due to insomnia
- Maximize 1 agent PRIOR to altering regimen.
- If refractory to all above measures, may trial Geodon (max: 40mg BID); if unsuccessful, consider Psychiatry consult
- Monitor QTc monitoring if receiving multiple QT-prolonging medications. Modify QT-prolonging medications if QTcF > 500.
- Avoid large doses of haloperidol in TBI
References:


**CAM ICU Assessment**

**Revised:** 5/2024, 4/2023, 3/2021

**Authors:**
*Jill Streams, MD*
*Bradley Dennis, MD*
*Abby Luffman, MSN, APN, AGACNP-BC*
*Bethany Evans, RN, MSN, ACNP-BC*
*Leanne Atchison, PharmD*